中創新航(03931.HK)被判停售侵害寧德時代(300750.SZ)專利產品並賠償損失 公司擬提上訴
中創新航(03931.HK)公布,有關寧德時代(300750.SZ)針對公司及寧德市星元汽車貿易就「集流構件和電池」提出的知識產權侵權索賠案,福州中院判決公司停止銷售侵害寧德時代發明專利權的產品,並賠償寧德時代經濟損失263.25萬元人民幣(下同),支付發明專利臨時保護期費用12.75萬元,以及賠付合理支出20萬元,另駁回寧德時代的其他訴訟請求。
該案案件受理費9.68萬元,由寧德時代負擔4.84萬元,中創新航負擔4.84萬元。
公司指出,公告判決為福州中院的一審判決,並非終審生效判決。公司將在上訴期內就該一審判決向最高院提出上訴,尚無法確定終審判決時間和結果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.